On-treatment PSA and disease burden should be considered together for prognostication. Achieving PSA ≤0.2 ng/mL within 6–12 weeks strongly predicts favorable long-term survival. Metastatic volume and ...

Dr. Alexander Decruyenaere presented the poster Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years? Dr.

Presented at ASCO 2021 by Dr. de Bono, gumelutamide (TAS3681) is a third generation androgen receptor antagonist targeting the ligand binding domain, but this agent also had minimal activity based on ...

Dr. Ignacio Duran titled his discussion of abstracts 2595MO, 2600MO, 2610MO: Bringing any clarity into the non-clear or ...

In the phase 1 portion of the trial, two doses of gedatolisib were administered IV on an intermittent schedule (Days 1, 8, 15 ...

HER-2 targeted antibody-drug conjugate monotherapy has demonstrated efficacy in the post-chemotherapy setting for ...

Dr. Laurence Albiges presented the poster Characteristics and real-world adherence to ESMO guidelines of patients with advanced Renal Cell Carcinoma (aRCC) in the era of immuno-oncology-based (IO) ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany, was host to the session Mini Oral session 2: GU tumours, renal & urothelial Dr. Tian Zhang ...

Of testicular cancer survivors aged <30 years at diagnosis, 60% fathered a post-index child, compared to 73% of the controls (p<0.001). Testicular cancer survivors aged ≥30 years had considerably ...

Dr. Ma emphasized that intratumor mycobiome dysbiosis is correlated with Clear Cell Renal Cell Carcinoma (ccRCC). He presented findings from an analysis of fungal communities in ccRCC, using ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between September 17 th and 21 st was host to the session Mini oral session: GU tumours, ...

Progression-free survival on first subsequent therapy (i.e., PFS2) was significantly prolonged with both enzalutamide ...